Evidence map›Paper›PMID 39147028›Full record

ReviewMolecular & cellular proteomics : MCP2024

Secretome Analysis Using Affinity Proteomics and Immunoassays: A Focus on Tumor Biology.

Vanessa M Beutgen, Veronika Shinkevich, Johanna Pörschke, Celina Meena, Anna M Steitz, Elke Pogge von Strandmann, Johannes Graumann, María Gómez-Serrano

Abstract readReview
In one paragraph

Review in Molecular & cellular proteomics : MCP, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Vanessa M BeutgenInstitute of Translational Proteomics, Biochemical/Pharmacological Centre, Philipps University, Marburg, Germany; Core Facility Translational Proteomics, Biochemical/Pharmacological Centre, Philipps University, Marburg, Germany.
Veronika ShinkevichInstitute of Pharmacology, Biochemical/Pharmacological Centre, Philipps University, Marburg, Germany.
Johanna PörschkeInstitute for Tumor Immunology, Center for Tumor Biology and Immunology, Philipps University, Marburg, Germany.
Celina MeenaInstitute for Tumor Immunology, Center for Tumor Biology and Immunology, Philipps University, Marburg, Germany.
Anna M SteitzTranslational Oncology Group, Center for Tumor Biology and Immunology, Philipps University, Marburg, Germany.
Elke Pogge von StrandmannInstitute for Tumor Immunology, Center for Tumor Biology and Immunology, Philipps University, Marburg, Germany.
Johannes GraumannInstitute of Translational Proteomics, Biochemical/Pharmacological Centre, Philipps University, Marburg, Germany; Core Facility Translational Proteomics, Biochemical/Pharmacological Centre, Philipps University, Marburg, Germany. Electronic address: johannes.graumann@uni-marburg.de.
María Gómez-SerranoInstitute for Tumor Immunology, Center for Tumor Biology and Immunology, Philipps University, Marburg, Germany. Electronic address: gomezser@staff.uni-marburg.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The study of the cellular secretome using proteomic techniques continues to capture the attention of the research community across a broad range of topics in biomedical research. Due to their untargeted nature, independence from the model system used, historically superior depth of analysis, as well as comparative affordability, mass spectrometry-based approaches traditionally dominate such analyses. More recently, however, affinity-based proteomic assays have massively gained in analytical depth, which together with their high sensitivity, dynamic range coverage as well as high throughput capabilities render them exquisitely suited to secretome analysis. In this review, we revisit the analytical challenges implied by secretomics and provide an overview of affinity-based proteomic platforms currently available for such analyses, using the study of the tumor secretome as an example for basic and translational research.

Indexed as

NeoplasmsProteomicsAnimalsHumansImmunoassayMass SpectrometrySecretomeaffinity proteomicsantibody arraysextracellular vesiclesimmunoassaysOlinkRPPAsecretomeSomaScan

Identifiers

PMID39147028
PMCPMC11417252

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.